Current Research: Pediatric Hematology-Oncology

ACCRN07 -- Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor

The primary objective of this study is to compare the overall survival of patients with clinical Stage II and III rectal cancer who received pre-operative chemoradiation and were treated with oxaliplatin, leucovorin, and 5-fluorouracil with or without bevacizumab postoperatively.

Eligibility

All new patients seen in COG member institutions with any of the following diagnoses are eligible:

• All cancer cases with an ICD-O histologic behavior code of two “2” (carcinoma in situ) or three “3” (malignant).
• All lesions of the central nervous system regardless of behavior, i.e., benign, borderlineor malignant.
• The benign / borderline conditions which will be reportable by agreement shall include:
  • Mesoblastic nephroma.
  • All teratomas, regardless of locations.
  • Theca cell – granulosa cell tumor.
  • Lymphoproliferative disease.
  • Ganglioneuroma
  • Myeloproliferative disease
  • Langerhan’s Cell histiocytosis

Trial Sponsor

• Children’s Oncology Group (COG)

Project Begin Date

• Feb 2008

Tentative Project End Date

• Ongoing

Back to Pediatric Hematology-Oncology Research

Revised March 30, 2009.   Please send comments, suggestions or questions about this page to Goldei Posey, gposey@mcg.edu .